

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

PerCP/Cyanine5.5 anti-human CD19

RRID:AB_2073119

Type: Antibody

Proper Citation

BioLegend Cat# 302230, RRID:AB_2073119

Antibody Information

URL: http://antibodyregistry.org/AB_2073119

Proper Citation: BioLegend Cat# 302230, RRID:AB_2073119

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_2073119

Vendor: BioLegend

Catalog Number: 302230

Alternative Catalog Numbers: 302229

Record Creation Time: 20250820T071936+0000

Record Last Update: 20250821T020628+0000

Ratings and Alerts

- Used for immunohistochemistry by the Human Islet Research Network community. Contact(s): [Leonard Shultz](#), [Todd Brusko](#), [Mark Atkinson](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for PerCP/Cyanine5.5 anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pi R, et al. (2025) NKp30 and NKG2D contribute to natural killer cell-mediated recognition of HIV-infected cells. *iScience*, 28(10), 113548.

Taguchi A, et al. (2025) Multifaceted profiling of virus-specific CD8 T cells reveals distinct immune signatures against cytomegalovirus infection states during pregnancy. *iScience*, 28(5), 112416.

Wagoner ZW, et al. (2025) Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. *Cell stem cell*, 32(4), 529.

Barlow KA, et al. (2025) Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies. *mAbs*, 17(1), 2479531.

Yamada K, et al. (2024) Protocol for immunophenotyping out-of-hospital cardiac arrest patients. *STAR protocols*, 5(1), 102874.

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon- γ 2a. *Cell*, 187(5), 1238.

Xie X, et al. (2024) Decoding human bone marrow hematopoietic stem and progenitor cells from fetal to birth. *iScience*, 27(8), 110445.

Massenet-Regad L, et al. (2023) Large-scale analysis of cell-cell communication reveals angiogenin-dependent tumor progression in clear cell renal cell carcinoma. *iScience*, 26(12), 108367.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. *Cell reports*, 42(6), 112657.

Zhou P, et al. (2023) Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. *Immunity*, 56(3), 669.

Tobin RP, et al. (2023) Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 29(7), 1209.

Falquet M, et al. (2023) Dynamic single-cell regulomes characterize human peripheral blood innate lymphoid cell subpopulations. *iScience*, 26(9), 107728.

Sponaugle A, et al. (2023) Dominant CD4⁺ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. *Cell reports. Medicine*, 4(11), 101268.

Perrett HR, et al. (2023) Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies. *Cell reports*, 42(5), 112524.

Zheng Z, et al. (2022) Uncovering the emergence of HSCs in the human fetal bone marrow by single-cell RNA-seq analysis. *Cell stem cell*, 29(11), 1562.

Kimura I, et al. (2022) The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. *Cell reports*, 38(2), 110218.

Abolhalaj M, et al. (2022) Transcriptional profiling demonstrates altered characteristics of CD8⁺ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia. *Cancer medicine*, 11(15), 3023.

Höfle J, et al. (2022) Engagement of TRAIL triggers degranulation and IFN γ production in human natural killer cells. *EMBO reports*, 23(8), e54133.

Japp AS, et al. (2021) TCR⁺/BCR⁺ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes. *Cell*, 184(3), 827.

Motozono C, et al. (2021) SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. *Cell host & microbe*, 29(7), 1124.